Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial

Biotech

Regeneron Strikes Deal With Trump Administration To Cut Drug Prices
Regeneron Strikes Deal With Trump Administration To Cut Drug Prices
AbbVie Faces FDA Rejection On Manufacturing Issues For Wrinkle Drug
AbbVie Faces FDA Rejection On Manufacturing Issues For Wrinkle Drug
Novo Nordisk Eyes Approval For Potential First Oral GLP-1 Diabetes Pill In Young Patients
Novo Nordisk Eyes Approval For Potential First Oral GLP-1 Diabetes Pill In Young Patients
AbbVie Faces FDA Rejection On Manufacturing Issues For Wrinkle Drug
AbbVie Faces FDA Rejection On Manufacturing Issues For Wrinkle Drug
Novo Nordisk Eyes Approval For Potential First Oral GLP-1 Diabetes Pill In Young Patients
Novo Nordisk Eyes Approval For Potential First Oral GLP-1 Diabetes Pill In Young Patients
FDA Approval Broadens Dupixent Use While Sanofi Posts Earnings Beat
FDA Approval Broadens Dupixent Use While Sanofi Posts Earnings Beat
Grace Therapeutics Stock Falls As FDA Declines To Approve Brain Hemorrhage Drug
Grace Therapeutics Stock Falls As FDA Declines To Approve Brain Hemorrhage Drug

Biotech Recent News

What's Going On With Arcus Biosciences Stock On Wednesday?
What's Going On With Arcus Biosciences Stock On Wednesday?
Arcus Biosciences halts STAR-121 lung cancer trial after futility review while Gilead Science declines option extension.
Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges
Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges
Inhibrx explores spin-off of INBRX-106 amid Big Pharma interest, with potential valuation exceeding $9 billion pending trial outcomes.
EXCLUSIVE: Adial Pharmaceuticals Clears Manufacturing Milestone Ahead Of Pivotal Study For Alcohol Use Disorder Drug
EXCLUSIVE: Adial Pharmaceuticals Clears Manufacturing Milestone Ahead Of Pivotal Study For Alcohol Use Disorder Drug
Adial Pharmaceuticals completes AD04 demo batch, validating process transfer and enabling Phase 3 production and FDA IND updates.
Sanofi Eyes First On-Body Injector Cancer Therapy As FDA Delays Decision
Sanofi Eyes First On-Body Injector Cancer Therapy As FDA Delays Decision
Sanofi says FDA delays Sarclisa SC review to July while expanding Tzield use to younger children with type 1 diabetes.
Kyverna Therapeutics (KYTX) Stock Surges 24% After Hours: Why Is It Moving?
Kyverna Therapeutics (KYTX) Stock Surges 24% After Hours: Why Is It Moving?
Kyverna Therapeutics Inc. shares surged 24% after hours following positive registrational trial results for miv-cel in stiff person syndrome, showing significant improvement in walking speed.
Europe Clears First Flu/COVID Combo Shot From Moderna
Europe Clears First Flu/COVID Combo Shot From Moderna
Moderna stock rises after EU approval of flu-COVID combo vaccine mCOMBRIAX, backed by Phase 3 data showing strong immune response.
Danaher Q1 Earnings Beat Estimates, But Revenue Miss, Weak Diagnostics Weigh On Stock
Danaher Q1 Earnings Beat Estimates, But Revenue Miss, Weak Diagnostics Weigh On Stock
Danaher Q1 earnings beat estimates as bioprocessing drives growth, while diagnostics weakens, and the respiratory outlook is lowered.
BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans
BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans
BioAge Labs says BGE-102 Phase 1 data show strong hsCRP reductions at 60 mg and 120 mg; analysts maintain Buy ratings with higher targets.
Anthony Scaramucci-Linked AlphaTON (ATON) Rebrands As Alpha Compute In 'Hard To Do' AI Pivot, CEO Terms Nvidia GPUs As 'Core' Balance Sheet Assets
Anthony Scaramucci-Linked AlphaTON (ATON) Rebrands As Alpha Compute In 'Hard To Do' AI Pivot, CEO Terms Nvidia GPUs As 'Core' Balance Sheet Assets
AlphaTON Capital Corp. (NASDAQ:ATON) rebranded as Alpha Compute Corp. on Monday, with shares set to begin trading under the new ticker “ALP,” m
Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says
Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says
Stifel initiates coverage on Immunic (IMUX) with a Buy rating. Analysts see potential for VidoCa to disrupt the MS market via better safety.
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved